These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 11207053)

  • 1. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
    de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
    Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
    Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
    J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Biochem Pharmacol; 1999 Mar; 57(6):673-80. PubMed ID: 10037453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.
    Houba PH; Boven E; Erkelens CA; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 1998 Dec; 78(12):1600-6. PubMed ID: 9862570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
    Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
    Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
    Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
    de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
    Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
    Bosslet K; Czech J; Hoffmann D
    Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
    Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
    Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detecting doxorubicin concentration in KBv200 and KB cell xenografts in nude mice by high-performance liquid chromatography].
    Deng WJ; Zeng ZL; Liang YJ; Dai CL; Zhang JY; Fu LW
    Ai Zheng; 2008 Apr; 27(4):364-8. PubMed ID: 18423121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
    Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
    Boven E; de Jong J; Kuiper CM; Bast A; van der Vijgh WJ
    Eur J Cancer; 1996 Jul; 32A(8):1382-7. PubMed ID: 8869103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
    Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M
    Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice].
    Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L
    Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.